Waters Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development
ASMS 2022 – Waters Corporation (NYSE:WAT) today unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry (ASMS) 2022 Annual Conference. The products include the new Xevo™ G3 quadrupole time-of-flight (QTof) mass spectrometer, CONFIRM Sequence - a new oligonucleotide sequencing confirmation app for the waters_connect™ software platform and an electrospray ionization source for the high-resolution Waters™ SELECT SERIES™ Multi-Reflecting Time of Flight (MRT) mass spectrometer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005253/en/
The new Xevo G3 QTof system is a high-performance, benchtop mass spectrometer for characterizing and quantifying thermally-fragile molecules in applications such as biotherapeutics, forensics, metabolite identification, metabolomics and extractables and leachables. (Photo: Business Wire)
“Innovation in mass spectrometry progresses rapidly. Our product introductions at this year’s ASMS benefit scientists throughout the drug development cycle,” said Jon Pratt, Senior Vice President, Waters Corporation. “For researchers, this means enhanced capability to answer fundamental scientific questions. For the analytical scientist compiling analytical data for new drug filings, it means increased certainty and confidence in knowing precisely what’s in their samples and in what quantities.”
Waters Xevo G3 QTof – A Laboratory Workhorse
The new Xevo G3 QTof system is a high-performance, benchtop mass spectrometer for characterizing and quantifying molecules in applications such as biotherapeutics, forensics, metabolite identification, metabolomics and extractables and leachables. The Xevo G3 QTof system is up to 10X more sensitive than its class-leading predecessor at transmitting thermally fragile molecules and excels at measuring and characterizing denatured or native proteins, peptides and other biotherapeutics.
“Biopharmaceutical development and commercialization requires a deep understanding of product variation, their degradation pathways and the processes that make them,” said Dr. Andrew Mahan, Associate Director, Mass Spectrometry Group Leader, Cell Engineering and Early Development, Janssen. “The extended mass-to-charge ratio (m/z) range of the Xevo G3 QTof is going to be ideal for the analysis of multi-specifics and for native MS analyses.”
Waters engineered the Xevo G3 QTof system to reliably give scientists both reproducible and accurate qualitative and quantitative information about molecules in their samples whether in very small or very large amounts.
New Software App for Confirming Nucleic Acid Sequence of Biotherapeutics
The CONFIRM Sequence app on the waters_connect software platform helps scientists using a Waters LC-MS System to confirm the nucleic acid sequence of therapeutics and identify impurities that could compromise product safety and efficacy.
The CONFIRM Sequence app eliminates 50% of the time it takes for post-processing data review, accelerating characterization and development of nucleic acid therapeutics.iii
The new CONFIRM Sequence app is the first sequencing tool to integrate compliance-ready data acquisition, processing, and reporting - making it ideal for deployment in regulated development and Good Manufacturing Practice (GMP) labs.
Coupling UPLC™ to Waters MRT SELECT SERIES Research Mass Spectrometer with ESI Source for Fast Molecular Characterization
The Waters SELECT SERIES MRT System is now compatible with UPLC-MS with an available electrospray ionization (ESI) source. Coupling the high resolution MRT System with the ESI source enables scientists to accurately resolve and measure low (<200 ppb) concentrations of sample analytes at UPLC acquisition speeds for metabolomics, metabolite identification or peptide mapping applications.
The superior performance of the SELECT SERIES MRT allows scientists to get the highest quality mass spectrometry data and information faster than any commercial mass spectrometer on the market today, giving scientists a much clearer picture of the structure of their molecules at the isotope level iv.
- View Waters ASMS 2022 Online Media Kit for downloadable photos and content
- Download the Waters Xevo G3 QTof brochure
- Download the poster A New Software Tool for Sequence Confirmation and Impurity Analysis of Synthetic Oligonucleotides
- Follow and connect with Waters via LinkedIn, Twitter, and Facebook
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.
Waters, Xevo, SELECT SERIES, UPLC and waters_connect are trademarks of Waters Corporation.
i Vs. the Waters Xevo G2-XS
ii For thermally-labile compounds
iii Internal estimate based on 30 minutes to review a single oligo sequence data set in CONFIRM Sequence compared to 90 minutes with ThermoFisher’s BioPharma Finder.
iv Waters SELECT SERIES MRT mass resolution >200k FWHM @ m/z 785 and independent of scan time; highest resolution achieved irrespective of scan rate
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Brian J. Murphy
PR Manager, Corporate Communications
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Time Manufacturing Company Acquires France Elévateur27.6.2022 12:00:00 CEST | Press release
H.I.G. Capital ("H.I.G."), a leading global alternative investment firm with over $49 billion of equity capital under management, is pleased to announce that its portfolio company, Time Manufacturing Holdings, LLC (“Time Manufacturing” or the “Company”), a leading, global provider of vehicle-mounted aerial lifts, has acquired France Elévateur (“FE Group”). The pairing of the two companies, who share a mutual dedication to quality and safety, strengthens the combined platform’s global manufacturing capabilities while enhancing value to customers through a broader portfolio of complementary products and services. Founded in 1984 and headquartered in Flavigny, France, France Elévateur is a leading manufacturer of vehicle-mounted aerial platforms for customers in various trades including public lighting, electric utility, roofing, telecommunications, rail networks, and other fields requiring access solutions. Through its two manufacturing sites in France and Spain and its footprint of 15 s
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine27.6.2022 12:00:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD) were recently published in the New England Journal of Medicine (NEJM) and presented in an oral presentation at The International Liver Congress™ 2022 - The Annual Meeting of the European Association for the Study of the Liver (EASL). The NEJM article was published online ahead of print and is titled, “Fazirsiran for Liver Disease Associated with Alpha-1 Antitrypsin Deficiency.” The EASL presentation was titled, “Reduction of Intra-hepatic Z-AAT Synthesis by Fazirsiran Decreases Globule Burden and Improves Histological Measures of Liver Disease in Adults with Alpha-1 Antitrypsin Deficiency.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/ho
Seoul Viosys 'Violeds' UV-C Technology Applied to 30,000 Cubic Meters Per Day for Municipal Water Purification System from Typhon Treatment Systems27.6.2022 10:45:00 CEST | Press release
Seoul Viosys (KOSDAQ: 092190), a company specializing in optical semiconductors, announced that the ‘Violeds’ technology was supplied to Typhon Treatment Systems Ltd., a British water treatment company, and applied to the UK's Cumbria water purification plant with a daily water purification capacity of 30,000 cubic meters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005267/en/ Typhon’s integrated array of ‘Violeds’ UV LEDs inside water pipe (Photo: Business Wire) UV lamp sterilization using mercury has been used in water purification facilities for the past several decades, and despite the restrictions on mercury products by the Minamata Convention, it was difficult to replace the sterilization performance, so it was subject to special permission. However, Violeds uses LEDs as a UV source, so it does not use mercury and reduces the amount of chemicals used for sterilization, thereby reducing the occurrence of enviro
Topdanmark deploys Guidewire for reduced IT complexity and omnichannel customer engagement27.6.2022 10:00:00 CEST | Press release
Guidewire (NYSE: GWRE) today announced that Topdanmark, Denmark’s second largest insurance company, has implemented Guidewire to lower IT architecture complexity and focus on the development of a strong platform with streamlined systems. The implementation will enable Topdanmark to engage more effectively with customers across multiple channels, to digitize policy and billing processes, and enable self-service functionality. Guidewire has been deployed to Topdanmark’s wind turbine, property, and content lines of business in their Agriculture division. This has been in parallel with deployment of a Salesforce platform that is deeply integrated with Guidewire. Further Guidewire deployments are planned in 2022 for their Private and Commercial divisions. "It has been vital for us to get the cornerstone right from the beginning by creating basic Danish insurance processes, integrations, and customer communication,” said Monica Diaz, Head of Agriculture and Commercial division. "With the cor
Paul Fry appointed as Argenta’s new Chief Financial Officer27.6.2022 08:59:00 CEST | Press release
Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately. To ensure a smooth transition, Paul will work closely with former CFO Chris O’Donnell until late August. The CFO role is being relocated from New Zealand to London to enable the CEO and CFO to work closely together in the same time zone, and to be closer to customers and new commercial opportunities. Chris O’Donnell, who has served as Argenta’s CFO since 2018, is supportive of the decision and has decided to stay in New Zealand. He stepped down from his role on June 24 and will stay on until August 26 to support with the transition. Chris has played a leading role in the success and growth of Argenta, providing skilful oversight to key projects including the transition of ownership to KKR and the acquisition of Klifovet. Paul Fry has extensive financial experience across several industries including biotech, pharmaceuticals, and telecommunications. Prior to joining Arge